Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keating

Showing results (961-970 of 1,115) with videos related to

Pageof 112
Sort By:
Blood|December 1, 2010
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaMariela Sivina, Elena Hartmann, Thomas J Kipps, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
The New England Journal of Medicine|August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaLaura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
Blood|September 19, 2009
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceAntonina V Kurtova, Kumudha Balakrishnan, Rong Chen, et al.
Blood|December 4, 2008
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensKatherine I Lin, Constantine S Tam, Michael J Keating, et al.
Leukemia & Lymphoma|March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinionSteven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsCandida Vitale, Lorenzo Falchi, Elisa Ten Hacken, et al.
Blood|March 11, 2008
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selectionEmanuela M Ghia, Sonia Jain, George F Widhopf, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
Maternal and fetal HLA heterozygosity in preeclampsia: Insights from a large multi-ancestry pregnancy cohortChang Cao, Matthew Maher, Jie Hu, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 7, 2019
Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groupsMoataz E Mohamed, David P Schladt, Weihua Guan, et al.
Pageof 112

Showing results (961-970 of 1,115) with videos related to

Sort By:
Pageof 112
Blood|December 1, 2010
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaMariela Sivina, Elena Hartmann, Thomas J Kipps, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
The New England Journal of Medicine|August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaLaura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
Blood|September 19, 2009
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceAntonina V Kurtova, Kumudha Balakrishnan, Rong Chen, et al.
Blood|December 4, 2008
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensKatherine I Lin, Constantine S Tam, Michael J Keating, et al.
Leukemia & Lymphoma|March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinionSteven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsCandida Vitale, Lorenzo Falchi, Elisa Ten Hacken, et al.
Blood|March 11, 2008
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selectionEmanuela M Ghia, Sonia Jain, George F Widhopf, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
Maternal and fetal HLA heterozygosity in preeclampsia: Insights from a large multi-ancestry pregnancy cohortChang Cao, Matthew Maher, Jie Hu, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 7, 2019
Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groupsMoataz E Mohamed, David P Schladt, Weihua Guan, et al.
Pageof 112